UNITED STATES

SECURITIES AND EXCHANGE COMMISSION ~~Washington, D.C. 20549~~

Washington, D.C. 20549

______________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

~~December 2, 2007~~ Date of Report – April 30, 2008

CHEMOKINE THERAPEUTICS CORP.

(Exact name of registrant as specified in charter)

Delaware	~~333~~000-~~117858~~51080	33-0921251
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

6190 Agronomy Road, Suite 405

University of British Columbia

Vancouver, British Columbia

V6T 1Z3

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code (604) 822-0301

N/A

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~ITEM 58.0201. ~~Departure~~Other ~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Events.

On ~~December~~April 330, ~~2007~~2008, ~~Mr.~~Chemokine CTherapeutics Corp. ~~Richard~~(the ~~Piazza~~“Company”) ~~tendered~~issued ~~his resignation~~a aspress ~~Chief~~release ~~Executive~~announcing ~~Officer~~research ofresults ~~Chemokine~~which ~~Therapeutics~~were ~~Corp~~presented by Dr. (Ronnie Poon, from the ~~“Company”)~~ ~~effective~~Department ~~December~~of 3Surgery, ~~2007.~~University Mrof Hong Kong at the American Association for Cancer Research (AACR) Annual Meeting. ~~Piazza~~The ~~will~~data ~~remain~~showed ~~Chairman~~a strong anti-tumor effect in a preclinical model of ~~the Board~~liver cancer.

~~Following~~A ~~the~~copy ~~resignation~~ of ~~Mr. Piazza,~~ the ~~Board~~press ofrelease ~~Directors of~~is ~~the~~attached ~~Company appointed Mr. Bashir Jaffer to serve~~ as ~~Interim~~exhibit ~~Chief Executive Officer until such time as the Company is able to locate a permanent Chief Executive Officer~~99.1 ~~Mr. Jaffer also continues~~ to ~~serve~~this inCurrent ~~his~~Report ~~role~~on asForm ~~Chief Financial Officer and Secretary of the Company~~8-K.

AsITEM ~~of December 4, 2007, Dr~~9. ~~Hassan Salari and the Company agreed to a voluntary reduction in the time he devotes serving as the Company’s Chief Scientific Officer to 50% of full time~~01. InFinancial ~~connection~~Statements ~~therewith, as of December 1, 2007, Dr. Salari’s annual salary will be reduced to C$157,500~~ and ~~he and the Company will enter into an amendment to his existing employment agreement to bring it in alignment with the foregoing terms~~Exhibits.

On(d) ~~December 2, 2007, Mr. Mohammed Azab tendered his resignation as a member of the Company’s board of directors effective December 4, 2007.~~Exhibits

Item 8.01. Other Events.


Exhibit Number	Description of Exhibit
99.1	Press Release

~~On December 4, 2007, the Company issued a press release relating to a corporate restructuring and personnel changes, a copy of which is attached hereto as Exhibit 99.1.~~SIGNATURE

~~Item~~Pursuant ~~9.01.~~to ~~Financial~~the ~~Statements~~requirements ~~and~~of ~~Exhibits~~the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

~~(d)~~Date: ~~Exhibits~~April 30, 2008 Chemokine Therapeutics Corp., a Delaware corporation By: /s/ Bashir Jaffer Bashir Jaffer Chief Financial Officer

Exhibit Number	Description of Exhibit
99.1	Press Release dated December 4, 2007

Exhibit 99.1

~~SIGNATURE~~CHEMOKINE THERAPEUTICS CORP.

~~Pursuant~~6190 toAgronomy ~~the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized~~Rd.

~~CHEMOKINE~~Suite ~~THERAPEUTICS CORP. By: /s/ Bashir Jaffer Bashir Jaffer Chief Executive Officer~~405

~~Dated: December 4th~~Vancouver, ~~2007~~BC

~~FOR~~V6T ~~IMMEDIATE RELEASE~~1Z3

~~CHEMOKINE~~Tel: ~~THERAPEUTICS~~(604) ~~WITHDRAWS REGISTRATION STATEMENT AND IMPLEMENTS A COST REDUCTION PLAN~~822-0301

~~Vancouver,~~Fax: BC (~~December 4, 2007~~604) ~~– Chemokine Therapeutics Corp. (the “Company”) (TSX:CTI, OTCBB:CHKT), a biotechnology company developing chemokine~~822-based therapies to treat cancer, blood disorders, and vascular diseases, today announced that the Company has withdrawn the registration statement relating to the public offering, announced on May 30, 2007, due to market conditions. The Company is currently evaluating financing alternatives to fund ongoing activities.0302

The Company has implemented a cost reduction plan that includes reducing the Company’s workforce by 65% which is expected to yield annual savings of approximately $1,500,000 in direct salaries and related costswww. ~~In addition, the remaining management has voluntarily agreed to a 10% reduction in their salaries~~chemokine. ~~This plan is designed to allow the Company to extend its financial resources and focus on essential operational activities for the continued development of its lead product candidates.~~net

AsNEWS part of the plan, Mr. C. Richard Piazza has resigned as Chief Executive Officer (“CEO”) of the Company and Mr. Bashir Jaffer, the Company’s Chief Financial Officer, has been appointed as Interim CEO. Mr. Piazza has accepted a position with another organization; however, he will continue to serve the Company as Chairman of the Board. Dr. Mohammad Azab has also tendered his resignation from the Board of Directors for personal reasons.RELEASE

~~The~~TSX: ~~Company~~CTI OTCBB: ~~would like to thank Mr. Piazza for serving as CEO for the past eight months and Dr. Azab for his services to the Company as a director for the past two years.~~CHKT

~~About~~CHEMOKINE ~~Chemokine~~THERAPEUTICS ~~Therapeutics~~ANNOUNCES ~~Corp.~~LIVER ~~(TSX:~~CANCER ~~CTI, OTCBB:~~DATA ~~CHKT) Chemokine~~PRESENTED Therapeutics is a product-focused biotechnology company developing drug candidates in the field of chemokines. Chemokines are a class of signaling proteins which play a critical role in the growth, differentiation, and maturation of cells necessary for fighting infection as well as tissue repair and regeneration. Chemokines also have an important role in cancer metastasis and growth. Chemokine Therapeutics is a leader in research in the field of chemokines and has several products in various stages of development.

~~Safe~~AT ~~Harbor~~THE ~~Statement~~AACR ~~under~~MEETING ~~the~~ON U.ITS S.LEAD ~~Private Securities Litigation Reform Act of 1995: Statements in this document regarding future expectations~~COMPOUND, ~~beliefs, goals, plans or prospects constitute forward~~CTCE-looking statements such as the Company’s expected benefits from its cost-saving initiatives and its ability to pursue additional funding alternatives. These forward looking statements involve risks and uncertainties that may cause actual results to differ materially from the forward looking statements made herein. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "projects", and similar expressions are intended to identify forward-looking statements. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to ,the Company’s ability to raise additional funding, those associated with the success of research and development programs, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, the potential dilutive effects of any future financing, reliance on subcontractors and key personnel and other risks detailed from time-to-time in the Company's public disclosure documents and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are made as of the date hereof, and the Company disclaims any intention and 9908

~~has~~Vancouver, noBC ~~obligation~~(April ~~or responsibility~~30, ~~except~~2008) ~~as required~~– byChemokine ~~law,~~Therapeutics toCorp. ~~update~~(“Chemokine Therapeutics” or ~~revise~~the ~~any~~“Company”) ~~forward~~(TSX:CTI, OTCBB:CHKT), a biotechnology company developing chemokine-~~looking~~based ~~statements~~therapies to treat cancer, ~~whether~~blood ~~as a~~disorders, ~~result~~and ofvascular ~~new~~disease ~~information~~today announced research results which were presented by Dr. Ronnie Poon, ~~future~~from ~~events~~the Department of Surgery, orUniversity ~~otherwise~~of Hong Kong at the American Association for Cancer Research (AACR) Annual Meeting. The data showed a strong anti-tumor effect in a preclinical model of liver cancer.

~~For~~Liver ~~further~~cancer ~~information~~in ~~contact: Chemokine Therapeutics~~humans ~~Corp~~is routinely treated with a combination surgical and chemotherapy procedure called transarterial chemoembolization (TACE). Mr Dr. ~~Don~~Poon ~~Evans Director~~measured an increase in bone marrow cells in patients with liver cancer one week after TACE therapy. These cells are responsible for repair and regrowth of ~~Public Relations Phone:~~the ~~(604)~~tumor ~~822-0305~~after orTACE ~~1-888-822-0305~~therapy. ~~Fax:~~Dr. ~~(604)~~Poon ~~822~~showed in his liver cancer animal model that after treatment with a surgical procedure that was equivalent to TACE, the tumor recurred through increasing recruitment of bone marrow support cells and new blood vessel formation. However, when the same surgical procedure was followed by treatment with CTCE-~~0302~~9908, Eit stopped the re-~~mail:~~growth ~~devans@chemokine~~of the tumor.~~net~~ ~~Internet:~~Recruitment ~~www~~of support cells and blood vessels were reduced, the tumor cells died and the tumor eventually disappeared.~~chemokine~~ Treatment with CTCE-9908 also showed a statistically significant increase in survival of approximately 50%, when compared to surgical treatment alone.~~net~~

“This data demonstrates our understanding of the duel mechanism provided by CTCE-9908 therapy. The compound not only interferes with the dissemination of cancer cells referred to as metastasis but in addition caused a profound decrease in the recruitment of those cells critical to the support and re-growth of a tumor that has been insulted by chemotherapy,” stated Walter Korz, President and Chief Executive Officer of the Company. “This data supports the basis for the design of our upcoming Phase II clinical trial in liver cancer.”

This poster is available on the Company website at www.chemokine.net.

About CTCE-9908

CTCE-9908 is a peptide analog of the chemokine SDF-1, and an antagonist of its receptor, CXCR4. SDF-1 is the only known naturally occurring chemokine that binds to CXCR4, which is present on many cancer cells as well as cancer support cells such as cells making up new blood vessels. This binding process is believed to be critical to cell migration. The anti-migration property of CTCE-9908 is pivotal in not only reducing recruitment of support cells that allow survival and growth of the primary tumor, but also metastasis (or spread) of cancer cells to distant locations in the body, where they form secondary tumors. Approximately 90% of cancer deaths are due to metastasis and disease progression. We believe that CTCE-9908 has the potential to shrink the primary tumor and delay the occurrence of new tumors due to its anti-angiogenic properties and anti-metastatic activity.

About Chemokine Therapeutics Corp. (TSX: CTI, OTCBB: CHKT)

Chemokine Therapeutics is a product-focused biotechnology company developing drug candidates in the field of chemokines. Chemokines are a class of signaling proteins that play a critical role in the growth, differentiation, and maturation of cells necessary for fighting infection as well as tissue repair and regeneration. Chemokines also have an important role in cancer metastasis and growth. Chemokine Therapeutics is a leader in research in the field of chemokines and has several products in various stages of development.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: Statements in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "projects", and similar expressions are intended to identify forward-looking statements. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, those associated with the success of research and development programs, the Company’s ability to raise additional funding and the potential dilutive effects thereof, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, reliance on subcontractors and key personnel and other risks detailed from time-to-time in the Company's public disclosure documents and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

For further information contact:

Chemokine Therapeutics Corp.

Mr. Don Evans

Vice President, Corporate Communications

Phone: (604) 822-0305 or 1-888-822-0305

Fax: (604) 822-0302

E-mail: devans@chemokine.net

Internet: www.chemokine.net

Filing Compare · CHEMOKINE THERAPEUTICS CORP